MedTrace Logo

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

NCT02057133 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2026-01-26

No results posted yet for this study

Summary

This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide, or ongoing endocrine therapy) for breast cancer that has spread to other parts of the body.

Conditions

  • Breast Neoplasms

Interventions

DRUG

LY2835219

Administered orally.

DRUG

Letrozole

Administered orally.

DRUG

Anastrozole

Administered orally.

DRUG

Tamoxifen

Administered orally.

DRUG

Exemestane

Administered orally.

DRUG

Everolimus

Administered orally.

DRUG

Trastuzumab

Administered IV infusion.

DRUG

LY3023414

Administered orally.

DRUG

Fulvestrant

Administered IM.

DRUG

Pertuzumab

Administered IV infusion.

DRUG

Loperamide

Administered orally.

DRUG

Endocrine therapy

Endocrine therapy administered orally.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-10
Primary Completion
2021-03-15
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02057133 on ClinicalTrials.gov